BACKGROUND: Androgen receptor targeted therapies have emerged as an effective tool to manage advanced prostate cancer (PCa). Nevertheless, frequent occurrence of therapy resistance represents a major challenge in the clinical management of patients, also because the molecular mechanisms behind therapy resistance are not yet fully understood. In the present study, we therefore aimed to identify novel targets to intervene with therapy resistance using gene expression analysis of PCa co-culture spheroids where PCa cells are grown in the presence of cancer-associated fibroblasts (CAFs) and which have been previously shown to be a reliable model for antiandrogen resistance. METHODS: Gene expression changes of co-culture spheroids (LNCaP and DuCaP seeded together with CAFs) were identified by Illumina microarray profiling. Real-time PCR, Western blotting, immunohistochemistry and cell viability assays in 2D and 3D culture were performed to validate the expression of selected targets in vitro and in vivo. Cytokine profiling was conducted to analyze CAF-conditioned medium. RESULTS: Gene expression analysis of co-culture spheroids revealed that CAFs induced a significant upregulation of cholesterol and steroid biosynthesis pathways in PCa cells. Cytokine profiling revealed high amounts of pro-inflammatory, pro-migratory and pro-angiogenic factors in the CAF supernatant. In particular, two genes, 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (HMGCS2) and aldo-keto reductase family 1 member C3 (AKR1C3), were significantly upregulated in PCa cells upon co-culture with CAFs. Both enzymes were also significantly increased in human PCa compared to benign tissue with AKR1C3 expression even being associated with Gleason score and metastatic status. Inhibiting HMGCS2 and AKR1C3 resulted in significant growth retardation of co-culture spheroids as well as of various castration and enzalutamide resistant cell lines in 2D and 3D culture, underscoring their putative role in PCa. Importantly, dual targeting of cholesterol and steroid biosynthesis with simvastatin, a commonly prescribed cholesterol synthesis inhibitor, and an inhibitor against AKR1C3 had the strongest growth inhibitory effect. CONCLUSIONS: From our results we conclude that CAFs induce an upregulation of cholesterol and steroid biosynthesis in PCa cells, driving them into AR targeted therapy resistance. Blocking both pathways with simvastatin and an AKR1C3 inhibitor may therefore be a promising approach to overcome resistances to AR targeted therapies in PCa. Video abstract.

Department of Clinical and Molecular Pathology Institute of Molecular and Translational Medicine Palacky University and University Hospital Olomouc Czech Republic

Department of Internal Medicine 4 Nephrology and Hypertension Medical University of Innsbruck Innsbruck Austria

Department of Plastic Reconstructive and Aesthetic Surgery Medical University of Innsbruck Innsbruck Austria

Department of Urology Division of Experimental Urology Medical University of Innsbruck Anichstrasse 35 6020 Innsbruck Austria

Institute of Legal Medicine Medical University of Innsbruck Innsbruck Austria

Salzburg Cancer Research Institute Laboratory for Immunological and Molecular Cancer Research Salzburg Austria

Tyrolean Cancer Research Institute Innsbruck Austria

See more in PubMed

Merseburger AS, Alcaraz A, von Klot CA. Androgen deprivation therapy as backbone therapy in the management of prostate cancer. Onco Targets Ther. 2016;9:7263–7274. doi: 10.2147/OTT.S117176. PubMed DOI PMC

Knudsen KE, Kelly WK. Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Rev Endocrinol Metab. 2011;6(3):483–493. doi: 10.1586/eem.11.33. PubMed DOI PMC

Puente J, Grande E, Medina A, Maroto P, Lainez N, Arranz JA. Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting. Ther Adv Med Oncol. 2017;9(5):307–318. doi: 10.1177/1758834017692779. PubMed DOI PMC

Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011;30(13):2719–2733. doi: 10.1038/emboj.2011.158. PubMed DOI PMC

Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate Cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71(2):151–154. doi: 10.1016/j.eururo.2016.07.032. PubMed DOI PMC

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. doi: 10.1056/NEJMoa1014618. PubMed DOI PMC

Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787–790. doi: 10.1126/science.1168175. PubMed DOI PMC

Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375(9724):1437–1446. doi: 10.1016/S0140-6736(10)60172-9. PubMed DOI PMC

Boudadi K, Antonarakis ES. Resistance to novel Antiandrogen therapies in metastatic castration-resistant prostate Cancer. Clin Med Insights Oncol. 2016;10(Suppl 1):1–9. PubMed PMC

Culig Z. Molecular mechanisms of Enzalutamide resistance in prostate Cancer. Curr Mol Biol Rep. 2017;3(4):230–235. doi: 10.1007/s40610-017-0079-1. PubMed DOI PMC

Eder Theresa, Weber Anja, Neuwirt Hannes, Grünbacher Georg, Ploner Christian, Klocker Helmut, Sampson Natalie, Eder Iris. Cancer-Associated Fibroblasts Modify the Response of Prostate Cancer Cells to Androgen and Anti-Androgens in Three-Dimensional Spheroid Culture. International Journal of Molecular Sciences. 2016;17(9):1458. doi: 10.3390/ijms17091458. PubMed DOI PMC

Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, et al. Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer. 1999;81:242–251. doi: 10.1038/sj.bjc.6690684. PubMed DOI PMC

Shalom Madar, Ran Brosh, Yosef Buganim, Osnat Ezra, Ido Goldstein, Hilla Solomon, Ira Kogan, Naomi Goldfinger, Helmut Klocker, Varda Rotter, (2009). PubMed PMC

Hoefer J, Akbor M, Handle F, Ofer P, Puhr M, Parson W, et al. Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide. Oncotarget. 2016;7(37):59781–94. PubMed PMC

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–408. doi: 10.1006/meth.2001.1262. PubMed DOI

Desiniotis A, Schafer G, Klocker H, Eder IE. Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase a. Int J Cancer. 2010;126(3):775–789. doi: 10.1002/ijc.24806. PubMed DOI

Vila-Brau A, De Sousa-Coelho AL, Mayordomo C, Haro D, Marrero PF. Human HMGCS2 regulates mitochondrial fatty acid oxidation and FGF21 expression in HepG2 cell line. J Biol Chem. 2011;286(23):20423–20430. doi: 10.1074/jbc.M111.235044. PubMed DOI PMC

Sigl R, Ploner C, Shivalingaiah G, Kofler R, Geley S. Development of a multipurpose GATEWAY-based lentiviral tetracycline-regulated conditional RNAi system (GLTR) PLoS One. 2014;9(5):e97764. doi: 10.1371/journal.pone.0097764. PubMed DOI PMC

Hegardt FG. Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase: a control enzyme in ketogenesis. Biochem J. 1999;338(Pt 3):569–582. doi: 10.1042/bj3380569. PubMed DOI PMC

Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, et al. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res. 2012;72(23):6142–6152. doi: 10.1158/0008-5472.CAN-12-1335. PubMed DOI PMC

Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, et al. Intracrine androgens and AKR1C3 activation confer resistance to Enzalutamide in prostate Cancer. Cancer Res. 2015;75(7):1413–1422. doi: 10.1158/0008-5472.CAN-14-3080. PubMed DOI PMC

Hamid AR, Pfeiffer MJ, Verhaegh GW, Schaafsma E, Brandt A, Sweep FC, et al. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer. Mol Med. 2013;18:1449–1455. doi: 10.2119/molmed.2012.00296. PubMed DOI PMC

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197. doi: 10.1056/NEJMoa1207506. PubMed DOI

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433. doi: 10.1056/NEJMoa1405095. PubMed DOI PMC

Claessens F, Helsen C, Prekovic S, Van den Broeck T, Spans L, Van Poppel H, et al. Emerging mechanisms of enzalutamide resistance in prostate cancer. Nat Rev Urol. 2014;11(12):712–716. doi: 10.1038/nrurol.2014.243. PubMed DOI

Patel R, Fleming J, Mui E, Loveridge C, Repiscak P, Blomme A, et al. Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1. EMBO Mol Med. 2018;10(4). 10.15252/emmm.201708347. PubMed PMC

Nishida S, Hirohashi Y, Torigoe T, Nojima M, Inoue R, Kitamura H, et al. Expression of hepatocyte growth factor in prostate cancer may indicate a biochemical recurrence after radical prostatectomy. Anticancer Res. 2015;35(1):413–418. PubMed

Mi J, Hooker E, Balog S, Zeng H, Johnson DT, He Y, et al. Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate. J Biol Chem. 2018;293(52):20123–20136. doi: 10.1074/jbc.RA118.005395. PubMed DOI PMC

Li X, Liu Y, Wu B, Dong Z, Wang Y, Lu J, et al. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis. Oncol Rep. 2014;32(6):2605–2611. doi: 10.3892/or.2014.3511. PubMed DOI

Vanli N, Guo-Fu HU. Mechanism and function of Angiogenin in prostate Cancer. Zhongguo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao. 2015;31(12):1261–1266. PubMed PMC

Bochaton-Piallat Marie-Luce, Gabbiani Giulio, Hinz Boris. The myofibroblast in wound healing and fibrosis: answered and unanswered questions. F1000Research. 2016;5:752. doi: 10.12688/f1000research.8190.1. PubMed DOI PMC

Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019;18(1):70. doi: 10.1186/s12943-019-0994-2. PubMed DOI PMC

Chatterjee Aritrick, Watson Geoffrey, Myint Esther, Sved Paul, McEntee Mark, Bourne Roger. Changes in Epithelium, Stroma, and Lumen Space Correlate More Strongly with Gleason Pattern and Are Stronger Predictors of Prostate ADC Changes than Cellularity Metrics. Radiology. 2015;277(3):751–762. doi: 10.1148/radiol.2015142414. PubMed DOI

Byrns MC, Mindnich R, Duan L, Penning TM. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5alpha-reductase inhibitor finasteride. J Steroid Biochem Mol Biol. 2012;130(1–2):7–15. doi: 10.1016/j.jsbmb.2011.12.012. PubMed DOI PMC

Tian Y, Zhao L, Zhang H, Liu X, Zhao L, Zhao X, et al. AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression. Diagn Pathol. 2014;9:42. doi: 10.1186/1746-1596-9-42. PubMed DOI PMC

Henderson ST. Ketone bodies as a therapeutic for Alzheimer's disease. Neurotherapeutics. 2008;5(3):470–480. doi: 10.1016/j.nurt.2008.05.004. PubMed DOI PMC

Parker MR, Patel SM, Zachry JE, Kimball BA. Feminization of male Brown Treesnake methyl ketone expression via steroid hormone manipulation. J Chem Ecol. 2018;44(2):189–197. doi: 10.1007/s10886-018-0935-3. PubMed DOI

Brown MS, Goldstein JL. Heart attacks: gone with the century? Science. 1996;272(5262):629. doi: 10.1126/science.272.5262.629. PubMed DOI

Do R, Kiss RS, Gaudet D, Engert JC. Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway. Clin Genet. 2009;75(1):19–29. doi: 10.1111/j.1399-0004.2008.01099.x. PubMed DOI

Saraon P, Cretu D, Musrap N, Karagiannis GS, Batruch I, Drabovich AP, et al. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression. Mol Cell Proteomics. 2013;12(6):1589–1601. doi: 10.1074/mcp.M112.023887. PubMed DOI PMC

Yue S, Li J, Lee SY, Lee HJ, Shao T, Song B, et al. Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab. 2014;19(3):393–406. doi: 10.1016/j.cmet.2014.01.019. PubMed DOI PMC

Lee BH, Taylor MG, Robinet P, Smith JD, Schweitzer J, Sehayek E, et al. Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1. Cancer Res. 2013;73(3):1211–1218. doi: 10.1158/0008-5472.CAN-12-3128. PubMed DOI PMC

Adam RM, Mukhopadhyay NK, Kim J, Di Vizio D, Cinar B, Boucher K, et al. Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res. 2007;67(13):6238–6246. doi: 10.1158/0008-5472.CAN-07-0288. PubMed DOI

Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev. 2009;18(11):2807–2813. doi: 10.1158/1055-9965.EPI-09-0472. PubMed DOI PMC

Harshman LC, Wang X, Nakabayashi M, Xie W, Valenca L, Werner L, et al. Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate Cancer. JAMA Oncol. 2015;1(4):495–504. doi: 10.1001/jamaoncol.2015.0829. PubMed DOI PMC

Jung J, Lee C, Lee C, Kwon T, You D, Jeong IG, et al. Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer. Korean J Urol. 2015;56(9):630–636. doi: 10.4111/kju.2015.56.9.630. PubMed DOI PMC

Syvala H, Pennanen P, Blauer M, Tammela TL, Murtola TJ. Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells. Biochem Biophys Res Commun. 2016;481(1–2):46–50. doi: 10.1016/j.bbrc.2016.11.021. PubMed DOI

Yang L, Egger M, Plattner R, Klocker H, Eder IE. Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells. Urology. 2011;77(6):1508 e1–1508 e7. doi: 10.1016/j.urology.2010.12.074. PubMed DOI

Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst. 2008;100(21):1511–1518. doi: 10.1093/jnci/djn362. PubMed DOI

Liu C, Armstrong CM, Lou W, Lombard A, Evans CP, Gao AC. Inhibition of AKR1C3 activation overcomes resistance to Abiraterone in advanced prostate Cancer. Mol Cancer Ther. 2017;16(1):35–44. doi: 10.1158/1535-7163.MCT-16-0186. PubMed DOI PMC

Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers